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Pneumococcal pneumonia
David Goldblatt  ,1 Elizabeth Miller2
Pneumococcal conjugate vaccines (PCV) 
were first licensed in 2000 and have been 
introduced into national immunisation 
programme in more than 145 countries. 
They have had a profound effect on 
reducing invasive pneumococcal disease 
(IPD) caused by serotypes in the vaccine. 
These reductions have been seen both in 
infants immunised directly with PCV and 
in the general population protected indi-
rectly by reduced transmission of pneu-
mococci from immunised infants in whom 
the vaccine prevented nasopharyngeal 
carriage. PCV7 (Prevenar7, Pfizer, New 
York, NY, USA) was first introduced in the 
UK in 2006 followed by PCV13 (Prev-
enar13, Pfizer, New York, NY, USA) in 
2010. Both vaccines have had a striking 
impact on vaccine serotype IPD although 
a trend, seen first following PCV7, for an 
increase in IPD caused by serotypes not 
included in the vaccine(s) has been 
reported.1 Surveillance of the impact of 
PCVs is focused on IPD, defined as isola-
tion of pneumococcus from an otherwise 
sterile site, and has been the bedrock of 
monitoring the serotype- specific impact of 
vaccination at a population level for many 
years. It is however, well understood that 
from a numerical point of view, IPD is 
only the tip of the iceberg, with pneu-
monia and otitis media caused by Strepto-
coccus pneumoniae responsible for a much 
larger burden of disease.
In this edition of the journal, Pick 
and colleagues2 describe the outcome 
of their prospective population- based 
study of adult community acquired pneu-
monia (CAP) in two teaching hospitals 
in Nottingham, England. They focus on 
trends in pneumococcal serotype contri-
bution to the burden of adult CAP over 
5 years (2013–2018), a period associated 
with sustained high coverage of PCV13 
in the infant schedule.1 Attributing an 
episode of pneumonia to the pneumo-
coccus is complicated as blood cultures 
are only positive in approximately 10% 
of clinical episodes of pneumonia and 
the isolation of the pneumococcus from 
non- sterile sites such as sputum, lacks 
specificity for the underlying aetiology 
of a clinical episode of pneumonia. The 
ability to detect pneumococcal capsular 
antigen in the urine of patients with pneu-
mococcal disease has provided a sensitive 
and specific way of assessing, at the level of 
serotype, the contribution of the pneumo-
coccus to CAP in adults. Using a recently 
modified multiplex immunoassay to detect 
pneumococcal derived carbohydrate 
antigen in urine3 and an assay that detects 
a common pneumococcal cell wall carbo-
hydrate (C- polysaccharide) the authors 
were able to evaluate temporal changes in 
the incidence rate of hospitalised pneumo-
coccal CAP in adults (those over 15 years 
of age) and the specific contributions of 
the 24 serotypes measured in their assay.
The authors describe an increase in 
incidence of CAP overall and pneumo-
coccal CAP over this period, with the 
latter driven by the increase in non- 
vaccine pneumococcal CAP and serotype 
3 (ST3). Using incident rate ratios (IRRs) 
the authors reported a statistically signifi-
cant average annual increase of 19% over 
this 5- year period in CAP due to serotypes 
that are not represented in any currently 
licensed pneumococcal vaccine, including 
the 23 valent plain polysaccharide vaccine 
(PPV23). The only other pneumococcal 
CAP subgroup that showed a significant 
increase in IRR over the 5 years was the 
group of serotypes included in PCV13 and 
not PCV7 (PCV13non7). This category is 
however dominated by infection caused by 
serotype 3 (ST3) which in 2016/2017 and 
2017/2018 ST3 represented two- thirds of 
all PCV13non7 pneumococcal CAP cases.
This dominance of ST3 among the 
vaccine associated serotypes complicates 
other associations explored by the authors. 
For example, the authors attempted to 
identify potential risk factors in those 
whose pneumonia is due to serotypes 
contained in PCV13 compared with other 
serotypes, which might be informative 
for a risk based selective PCV13 strategy 
in adults. A number of risk factors were 
identified associated with an increased 
susceptibility to PCV13 serotype disease 
including increasing age, chronic kidney 
disease and other risk factors while living 
in residential care was associated with 
lower risk. However, none of these asso-
ciations were significant when ST3 was 
excluded from the analysis. The prepon-
derance of ST3 among VT pneumococcal 
CAP cases in the UK study is consistent 
with a recent study of CAP in the US4 and 
with the serotype distribution of IPD cases 
in both the UK and the USA1 5 and is a 
consequence of infant PCV13 immunisa-
tion having little impact on ST3 carriage.6
Since the overall CAP incidence itself 
irrespective of any vaccine effect may be 
influenced each year by external factors 
such as influenza or other respiratory 
viruses it is informative to look at the 
percentage of all adult CAP that is caused 
by vaccine serotypes. PCV7 attributable 
pneumonia was approximately 2% of total 
CAP during this period of study compared 
with 12.3% in 2008/9,7 soon after PCV7 
introduction. PCV13non7 attributable 
CAP (after exclusion of ST3) accounted 
for less than 5% of the total CAP in the 
last 3 years compared with 10.7% in 
2008/2009. This illustrates the beneficial 
impact of infant immunisation with PCV 
on adult VT CAP, at least in settings such 
as the UK which has achieved high PCV 
overage over many years. In such settings 
any additional benefit achieved by immu-
nisation of adults with PCVs containing 
the same serotypes as those used in infants 
would be small, although some direct 
protection in adults against ST3 CAP 
might be achieved.8
One- third of pneumococcal CAP in 
2017/18 (34%) was due to serotypes in 
the 23 valent vaccine but not in PCV13 
(PPV23non13); of these ST8 and ST12F 
were most prominent, serotypes also shown 
to be contributing to the increase in IPD 
in the UK.1 A lack of consistent evidence 
showing the effectiveness of PPV23 against 
CAP9 has led to PPV23non13 serotypes 
included in new extended multivalent 
pneumococcal conjugate vaccine being 
evaluated. Following licensure, the use of 
extended valency vaccines will be influ-
enced by a number of factors including 
their licensed indication (IPD or both IPD 
and pneumonia), the age group for which 
they are licensed (adults only or adults and 
children), their serotype composition and 
their likely cost effectiveness, bearing in 
mind that they will be licensed on immu-
nogenicity alone, and at the time of licen-
sure there will be no direct evidence for 
the ability of the vaccines to prevent CAP 
caused by the novel serotypes contained 
therein.
The limitation of evaluating urine with 
an assay that can only recognise 24 anti-
gens is apparent from the large increase 
in serotypes referred to by the authors as 
untyped. These episodes of pneumonia 
were associated with a positive C- polysac-
charide urinary antigen detection test but 
no confirmatory 24 valent bioplex results. 
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The study therefor fails to provide compre-
hensive information about emerging pneu-
mococcal strains which are not included in 
licensed vaccines. Furthermore, some of 
the monoclonal antibodies cross react with 
more than one pneumococcal capsule and 
for 11 of the 24 serotypes detected in the 
urine, the authors have been unable to cate-
gorically assign a serotype and have relied 
on a probabilistic technique based on domi-
nant serotypes in IPD. This is based on the 
assumption that a serotype causing pneu-
monia has a similar propensity for causing 
IPD which may not be the case. In partic-
ular, for two serotypes assigned causality in 
this way, 11A and 15A, there may be signif-
icant contributions from 16F and 15B/C, 
respectively.
Pick and colleagues2 provide useful infor-
mation on trends in adult pneumonia over 
the last 5 years and the effect of PCV vaccina-
tion on the proportion that is pneumococcal- 
attributable. Their analysis has shed light on 
the increase in adult hospital admissions due 
to pneumonia in recent years10 showing that 
this is attributable in part to pneumococcal 
serotype replacement. The observation that 
the majority of adult pneumonia secondary 
to serotypes effective in infant vaccines is 
reduced is reassuring and reinforces the 
need for maintaining high infant coverage. 
It also demonstrates that providing the same 
PCV as used in infants to adults is unlikely 
to have a big impact on CAP, an observation 
noted in the USA recently which led to the 
reversal of the former recommendation in 
the USA to use PCV in all adults over 65 
years of age.11 New conjugate vaccines with 
wider serotype coverage are in development 
but without a better understanding of the 
drivers of serotype replacement, especially 
among the elderly, their overall impact on 
pneumococcal disease in the future remains 
uncertain.
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